Trial Profile
A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary)
- Indications CNS cancer; Diffuse intrinsic pontine glioma; Glioma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 07 Jul 2023 Status changed from recruiting to discontinued as per sponsor decision.
- 27 Jan 2022 Planned End Date changed from 28 Jan 2025 to 20 Nov 2024.
- 27 Jan 2022 Planned primary completion date changed from 28 Jan 2025 to 20 Nov 2024.